PharmGKB and CPIC have signed up as supporters of H.R. 3235,
the ‘Access to Genetic Counselor Services Act’. This bill would improve access
to genetic counseling for Medicare beneficiaries by recognizing genetic
counselors as independent healthcare providers who can be reimbursed for their
services.
Dr. Teri Klein, co-PI of PharmGKB and CPIC, said: “Genetic
counselors are vital in bringing pharmacogenomics to the clinic and helping
patients to understand how their genetics can affect how they respond to drugs.
By supporting H.R. 3235, we hope that many more patients will be able to access
these services and receive expert advice about their genetic conditions”.
More information about H.R. 3235 can be found on the Congress.gov website.
Update 1/24/20 Comment from Dr. Teri Klein, co-PI of PharmGKB and CPIC: "For further clarification, genetic counselors are vital in bringing genomic medicine to the clinic of which pharmacogenomics is an important component."
Update 1/27/20 Comment from Julie Johnson, PharmD, Dean and Distinguished Professor, University of Florida College of Pharmacy; Founding Director, UF Health Precision Medicine Program and CPIC Steering Committee member: "I fully support qualified health professionals, who are important members of the healthcare team, being recognized with provider status. Two key groups that are seeking such status are genetic counselors and pharmacists. Genetic counselors are important team members for delivering genetic/genomic medicine and it is appropriate that they should be considered for provider status. However, I believe that PharmGKB and CPIC’s initial quote about the vital role of genetic counselors in pharmacogenetics is overstated. Based on my nearly decade-long experience leading the clinical use of pharmacogenetics data in our health system, it has become clear that the pharmaco- part of pharmacogenetics is what makes it difficult. Genetic data often tell us that a drug or dose is not right for a given patient, but a program is ineffective if it stops there. Guidance must also be provided on the alternative drug or dose that is right for that patient, and this requires expert knowledge in pharmacology, pharmacokinetics and pharmacotherapy. It is the rare genetic counselor that would be an expert in these things. Rather the members of the healthcare team best equipped for being “vital in bringing pharmacogenomics to the clinic and helping patients to understand how their genetics can affect how they respond to drugs” are pharmacists and those physicians who possess solid foundational knowledge in clinical pharmacology. This is not to diminish the important role of genetic counselors in patient care, but rather to say that the basis for them receiving provider status cannot be the role they play in clinical pharmacogenetics. If the focus is a highly effective healthcare team, then the members of the team must be included based on their expertise. In the case of clinical pharmacogenetics, those experts are most likely to be pharmacists and some physicians."
More information about H.R. 3235 can be found on the Congress.gov website.
Update 1/24/20 Comment from Dr. Teri Klein, co-PI of PharmGKB and CPIC: "For further clarification, genetic counselors are vital in bringing genomic medicine to the clinic of which pharmacogenomics is an important component."
Update 1/27/20 Comment from Julie Johnson, PharmD, Dean and Distinguished Professor, University of Florida College of Pharmacy; Founding Director, UF Health Precision Medicine Program and CPIC Steering Committee member: "I fully support qualified health professionals, who are important members of the healthcare team, being recognized with provider status. Two key groups that are seeking such status are genetic counselors and pharmacists. Genetic counselors are important team members for delivering genetic/genomic medicine and it is appropriate that they should be considered for provider status. However, I believe that PharmGKB and CPIC’s initial quote about the vital role of genetic counselors in pharmacogenetics is overstated. Based on my nearly decade-long experience leading the clinical use of pharmacogenetics data in our health system, it has become clear that the pharmaco- part of pharmacogenetics is what makes it difficult. Genetic data often tell us that a drug or dose is not right for a given patient, but a program is ineffective if it stops there. Guidance must also be provided on the alternative drug or dose that is right for that patient, and this requires expert knowledge in pharmacology, pharmacokinetics and pharmacotherapy. It is the rare genetic counselor that would be an expert in these things. Rather the members of the healthcare team best equipped for being “vital in bringing pharmacogenomics to the clinic and helping patients to understand how their genetics can affect how they respond to drugs” are pharmacists and those physicians who possess solid foundational knowledge in clinical pharmacology. This is not to diminish the important role of genetic counselors in patient care, but rather to say that the basis for them receiving provider status cannot be the role they play in clinical pharmacogenetics. If the focus is a highly effective healthcare team, then the members of the team must be included based on their expertise. In the case of clinical pharmacogenetics, those experts are most likely to be pharmacists and some physicians."
